Strides CEO: US COMPETES Act Creates Quality Differentiator
Examining Upcoming HIV Therapies
The $1m-$10m penalties prescribed on erring global manufacturers in the US COMPETES Act will create quality differentiators, Strides CEO R Ananthanarayanan believes. He also discusses the potential that Mark Cuban’s firm holds for Indian companies and Strides' evaluation of upcoming HIV therapies.
You may also be interested in...
Pharma Supply Chain Disruptions Increased Another 74% in 2021, Resilinc Says
The COVID-19 pandemic has both caused problems such as reduced preventive maintenance and exacerbated other issues, such as slowing recovery from extreme weather events, according to Resilinc CEO.
Piramal Invests Almost $75m In Expanding Manufacturing Capacity
Piramal Pharma’s Piramal Pharma Solutions contract development and manufacturing organization has invested around $75m in expanding its antibody-drug conjugate capabilities at its Grangemouth facility in Scotland and investing in a new active pharmaceutical ingredient infrastructure at the Morpeth facility in England.
US Supply Chain "Elasticity" Pilot Would Get Major Funds In House-Passed Legislation
COMPETES Act also includes enhanced penalties for drug makers who falsify or destroy records, power for the FDA to recall harmful drugs, funding for drug manufacturing technology and additional supply chain flexibility efforts.